Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › eptinezumab

eptinezumab

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of eptinezumab

5 trials tracked of eptinezumab: 5 in phase 3 or 4 and 5 with published results. The most-cited published study has 103 citations.

5Trials tracked
5Phase 3 & 4
0Recruiting
5With published results
Phase distribution
Phase 4 1 Phase 3 4
  1. Phase 3 A Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Participants Experiencing Acute Attack of Migraine Completed · 103 cited
  2. Phase 3 Eptinezumab in Participants With Episodic Cluster Headache Completed · 13 cited
  3. Phase 3 A 1-year Trial to Inform About Long-term Exposure to Eptinezumab in Participants With Chronic Cluster Headache (cCH) Completed · 12 cited
  4. Phase 3 A Study to Evaluate the Efficacy and Safety of Eptinezumab for the Prevention of Migraine in Participants That Are Not Helped by Previous Preventive Treatments Completed · 4 cited
  5. Phase 4 A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache Completed · 1 cited

Showing the 5 most-cited and recently-updated of 5 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Bayesian network meta-analysis compares CGRP therapies for episodic migraine
Neurology Meta-analysis
Bayesian network meta-analysis compares CGRP therapies for episodic migraine New migraine drugs show big benefits over placebo for monthly attack counts
This Bayesian network meta-analysis synthesized evidence on six CGRP-targeted therapies for episodic migraine. It found that monoclonal anti…
New migraine drugs cut monthly attacks more than placebo, with injectables slightly better than pills for some people.
medRxiv May 25, 2026
Preliminary Italian data show intravenous eptinezumab reduces pain and symptoms in patients with ongoing episodic or chronic migraine attacks
Neurology Cohort
Preliminary Italian data show intravenous eptinezumab reduces pain and symptoms in patients with ongoing episodic or chronic migraine attacks The Big Discovery:** A preventive migraine drug can start easing pain and light sensitivity during an ongoing attack—in as little as 10 minutes
This preliminary observational study enrolled 31 patients with episodic or chronic migraine experiencing an ongoing attack in an Italian rea…
For the first time, real-world data shows a migraine prevention treatment can also act with surprising speed to stop an attack that’s alread…
Frontiers Apr 10, 2026